Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Perazella, M. A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Nitric Oxide and Hemodialysis-Induced Hypotension

right arrow Mark A. Perazella, MD

15 February 1996 | Volume 124 Issue 4 | Page 454


TO THE EDITOR:

Yokokawa and colleagues [1] provide interesting data suggesting that increased nitric oxide production may contribute to the development of hemodialysis-induced hypotension. The authors speculate that individual patient sensitivity to heparin, an agent shown to promote nitric oxide production in cultured human vascular endothelial cells [2], may explain the increased production of nitric oxide seen in hypotensive patients, despite the administration of equal amounts of heparin. The mechanism by which increased nitric oxide production occurs, however, remains largely unknown.

Another complication of uremia—disordered hemostasis—is also thought to be related in part to platelet dysfunction associated with elevated nitric oxide levels [3, 4]. Interestingly, correction of anemia through transfusion or erythropoietin potentiates platelet function and improves the bleeding tendency associated with uremia. The effect of increased hematocrit to correct the uremic bleeding disorder may be related to the ability of the heme moiety to interfere with the release or production of nitric oxide [5]. A similar effect of increased hematocrit may blunt the nitric oxide-associated hypotension in patients receiving dialysis. Thus, it would be interesting to know whether a lower hematocrit or iron deficiency was present in the hypotensive group that had increased nitric oxide levels compared with the normotensive group.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Yale University School of Medicine; New Haven, CT 06510


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Yokokawa K, Mankus R, Saklayen MG, Kohno M, Yasunari K, Minami M, et al. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med. 1995; 123:35-7.

2. Yokokawa K, Tahara H, Kohno M, Mandal AK, Yanagiasawa M, Takeda T. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest. 1993; 92:2080-5.

3. Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Vigano G. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest. 1990; 86:1768-71.

4. Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int. 1993; 44:445-50.

5. Luscher TF, Bock HA, Yang Z, Diederich D. Endothelium-derived relaxing and contracting factors: perspectives in nephrology. Kidney Int. 1991; 39:575-90.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.




This article has been cited by other articles:


Home page
Arch Intern MedHome page
B. M. Rothschild
Apparent Warfarin Potency Inconsistencies Compromise Effectiveness
Arch Intern Med, May 26, 2003; 163(10): 1243 - 1243.
[Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Perazella, M. A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online